Figures computed from official regulatory filings — .
Analysttarget 30.67 USD (+127%) · consensus 4.83/5 · 6 buy · 0 hold · 0 sell
Ownershipinsiders 16.71% · institutions 55.88% · short 16.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for MediWound Ltd. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
7 buys1 sell— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Rubinstein Samueltrack record | Buy | $6.6K | conv 73Unusual size |
| SEC |
| Rubinstein Samueltrack record | Sell | $6.7K | SEC |
| SHAMIR NACHUMtrack record | Buy | $2.4K | conv 49ClusterFirst in 12mo | SEC |
| SHAMIR NACHUMtrack record | Buy | $81.6K | conv 61ClusterFirst in 12mo | SEC |
| Fox David Morton | Buy | $142.3 | conv 46First in 12mo | SEC |
| Fox David Morton | Buy | $24.6K | conv 50First in 12mo | SEC |
| Fox David Morton | Buy | $25.1K | conv 50First in 12mo | SEC |
| Rubinstein Samueltrack record | Buy | $2.1K | conv 37 | SEC |